Sanofi (SNY)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 01:41PM EDT. Market open.
| Previous close | 48.67 |
| Open | 48.39 |
| Bid | 48.54 x 100 |
| Ask | 48.59 x 100 |
| Day's range | 48.35 - 48.76 |
| 52-week range | 42.63 - 55.72 |
| Volume | |
| Avg. volume | 1,984,375 |
| Market cap | 122.496B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 24.64 |
| EPS (TTM) | 1.97 |
| Earnings date | 25 July 2024 |
| Forward dividend & yield | 2.04 (4.19%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | 59.90 |
ReutersShah Capital ends campaign against Novavax board after Sanofi deal
Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation. Novavax, which struggled to get its protein-based vaccine to the market in a timely manner, also removed a warning notice from February last year that raised doubts about it being in business after the deal. The fund, which owns an about 7.8% stake in Novavax, reiterated that the Sanofi agreement was a "long-awaited step in the right direction".
ZacksThe Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
ZacksBiotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
© 2024 Yahoo. All rights reserved.